Literature DB >> 8826957

Minimal disease detection in patients with alveolar rhabdomyosarcoma using a reverse transcriptase-polymerase chain reaction method.

K M Kelly1, R B Womer, F G Barr.   

Abstract

BACKGROUND: Polymerase chain reaction (PCR) assays that detect fusion genes resulting from consistent chromosomal translocations have been used to detect minimal residual disease, primarily in hematologic malignancies. Molecular assays have been developed recently that detect the PAX3-FKHR or PAX7-FKHR fusion transcript resulting from the t(2; 13) or t(1; 13) translocation consistently observed in alveolar rhabdomyosarcoma. Because of the tumor's propensity to disseminate widely, our aim was to determine whether or not reverse transcriptase-PCR assays could detect submicroscopic disease in bone marrow or peripheral blood specimens.
METHODS: We analyzed 19 bone marrow samples from 11 patients with a known gene fusion in their primary tumor. Specimens were collected at diagnosis, remission, and relapse. Fourteen peripheral blood samples were obtained serially from 5 of these patients. A reverse transcriptase-PCR assay was used to detect the presence of the PAX3-FKHR or PAX7-FKHR fusion transcript. These results were compared with the results of microscopic examination of the bone marrow. Medical records of all 11 patients were reviewed.
RESULTS: Adequate amplifiable RNA was obtained in 17 of 19 marrow samples. The PCR assay detected fusion products in all 4 specimens obtained from 3 patients with histologic evidence of bone marrow involvement. In addition, PAX3-FKHR fusion products were detected in bone marrows from 2 patients for whom there was no histologic evidence of disease. The fusion transcripts were not detected in any of the peripheral blood samples.
CONCLUSIONS: The detection of submicroscopic disease is possible in alveolar rhabdomyosarcoma patients using PCR. These assays may have a role in staging, monitoring therapy, purging protocols for autologous bone marrow transplantation, and post therapy follow-up. Larger prospective studies are needed to address the clinical relevance of these results.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8826957     DOI: 10.1002/(SICI)1097-0142(19960915)78:6<1320::AID-CNCR22>3.0.CO;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay.

Authors:  Soledad Gallego; Anna Llort; Josep Roma; Constantino Sabado; Luis Gros; Josep Sanchez de Toledo
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-25       Impact factor: 4.553

2.  Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.

Authors:  L Krsková; M Mrhalová; D Sumerauer; R Kodet
Journal:  Virchows Arch       Date:  2005-12-20       Impact factor: 4.064

Review 3.  Risk assignment in pediatric soft-tissue sarcomas: an evolving molecular classification.

Authors:  Stephen J Qualman; Raffaella A Morotti
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

4.  Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells.

Authors:  E S Massuda; E J Dunphy; R A Redman; J J Schreiber; L E Nauta; F G Barr; I H Maxwell; T P Cripe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma.

Authors:  Lenka Krsková; Marcela Mrhalová; Irena Hilská; David Sumerauer; Eva Drahokoupilová; Peter Múdry; Roman Kodet
Journal:  Virchows Arch       Date:  2010-04-20       Impact factor: 4.064

Review 6.  Circulating tumor cells in sarcomas: a brief review.

Authors:  Le Chang; Greg Asatrian; Sarah M Dry; Aaron W James
Journal:  Med Oncol       Date:  2014-12-10       Impact factor: 3.064

Review 7.  Molecular genetics of pediatric soft tissue tumors: clinical application.

Authors:  Chung-Che Chang; Vinod B Shidham
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

Review 8.  Molecular biology of rhabdomyosarcoma.

Authors:  S Gallego Melcón; J Sánchez de Toledo Codina
Journal:  Clin Transl Oncol       Date:  2007-07       Impact factor: 3.405

Review 9.  Molecular strategies for detecting chromosomal translocations in soft tissue tumors (review).

Authors:  Margherita Cerrone; Monica Cantile; Francesca Collina; Laura Marra; Giuseppina Liguori; Renato Franco; Annarosaria De Chiara; Gerardo Botti
Journal:  Int J Mol Med       Date:  2014-04-04       Impact factor: 4.101

Review 10.  Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice.

Authors:  Chiara Agnoletto; Chiara Caruso; Cecilia Garofalo
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.